Novavax (NASDAQ:NVAX) Price Target Cut to $110.00 by Analysts at Cowen
Novavax (NASDAQ:NVAX) Price Target Cut to $110.00 by Analysts at Cowen
Novavax (NASDAQ:NVAX – Get Rating) had its target price decreased by Cowen from $150.00 to $110.00 in a research report released on Tuesday, Stock Target Advisor reports.
據Stock Target Advisor報道，在週二發佈的一份研究報告中，考恩將諾華公司(納斯達克代碼：NVAX-GET評級)的目標價從150.00美元下調至110.00美元。
A number of other equities research analysts have also recently weighed in on NVAX. Cowen dropped their price target on shares of Novavax from $150.00 to $110.00 and set an outperform rating for the company in a research report on Tuesday. Cantor Fitzgerald raised their price objective on shares of Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th. Bank of America started coverage on shares of Novavax in a research note on Friday, May 20th. They issued an underperform rating and a $35.00 price objective for the company. Finally, B. Riley lowered their price objective on shares of Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, Novavax currently has an average rating of Hold and a consensus target price of $151.00.
其他一些股票研究分析師最近也加入了對NVAX的看法。考恩在週二的一份研究報告中將諾瓦克斯的目標價從150.00美元下調至110.00美元，併為該公司設定了表現優於大盤的評級。康託·菲茨傑拉德在6月8日星期三的一份研究報告中將諾華公司股票的目標價從146.00美元上調至168.00美元。美國銀行在5月20日星期五的一份研究報告中開始對Novavax的股票進行報道。他們發佈了表現不佳的評級和35.00美元的公司目標價。最後，B.Riley在7月22日星期五的一份研究報告中將諾華的股票目標價從181.00美元下調至171.00美元。一名股票研究分析師對該股的評級為賣出，3名分析師對該股給予持有評級，5名分析師對該公司給予買入評級。根據MarketBeat的數據，諾華目前的平均評級為持有，共識目標價為151.00美元。
Novavax Price Performance
Novavax性價比
Shares of NVAX opened at $40.28 on Tuesday. Novavax has a 1-year low of $34.88 and a 1-year high of $277.80. The stock has a market cap of $3.15 billion, a PE ratio of -2.28, a P/E/G ratio of 0.06 and a beta of 1.52. The firm has a 50-day simple moving average of $53.49 and a two-hundred day simple moving average of $63.48.
週二，NVAX的股價開盤報40.28美元。諾華的一年低點為34.88美元，一年高位為277.80美元。該股市值為31.5億美元，市盈率為-2.28，市盈率為0.06，貝塔係數為1.52。該公司的50日簡單移動均線切入位在53.49美元，200日簡單移動均線切入位在63.48美元。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd purchased a new position in Novavax in the first quarter worth approximately $9,839,000. IFM Investors Pty Ltd lifted its stake in Novavax by 19.6% in the first quarter. IFM Investors Pty Ltd now owns 11,096 shares of the biopharmaceutical company's stock worth $817,000 after acquiring an additional 1,819 shares during the last quarter. Nomura Asset Management Co. Ltd. lifted its stake in Novavax by 8.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 13,990 shares of the biopharmaceutical company's stock worth $2,002,000 after acquiring an additional 1,100 shares during the last quarter. Banque Cantonale Vaudoise lifted its stake in Novavax by 3,018.2% in the first quarter. Banque Cantonale Vaudoise now owns 11,631 shares of the biopharmaceutical company's stock worth $857,000 after acquiring an additional 11,258 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Novavax by 2.2% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 178,351 shares of the biopharmaceutical company's stock worth $13,136,000 after acquiring an additional 3,814 shares during the last quarter. Hedge funds and other institutional investors own 43.91% of the company's stock.
機構投資者最近增持或減持了該公司的股份。Qube Research&Technologies Ltd在第一季度購買了Novavax的一個新頭寸，價值約983.9萬美元。IFM Investors Pty Ltd在第一季度增持了19.6%的Novavax股份。IFM Investors Pty Ltd在上個季度增持了1,819股後，現在擁有這家生物製藥公司11,096股股票，價值817,000美元。野村資產管理有限公司(Nomura Asset Management Co.Ltd.)第四季度增持Novavax股份8.5%。野村資產管理有限公司(Nomura Asset Management Co.Ltd.)在上個季度增持了1,100股野村資產管理公司(Nomura Asset Management Co.)股票後，目前持有這家生物製藥公司13,990股股票，價值2,002,000美元。第一季度，Canonale Vaudoise銀行增持了Novavax 3018.2%的股份。Canonale Vaudoise銀行現在擁有這家生物製藥公司11631股票，價值85.7萬美元，在上個季度額外購買了11258股。最後，三井住友信託控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)在第一季度增持了Novavax 2.2%的股份。三井住友信託控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)目前持有這家生物製藥公司178,351股股票，價值13,136,000美元，該公司在上個季度增持了3,814股股票。對衝基金和其他機構投資者持有該公司43.91%的股份。
About Novavax
關於Novavax
(Get Rating)
(獲取評級)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Novavax，Inc.是一家生物技術公司，專注於疫苗的發現、開發和商業化，以預防嚴重的傳染病和滿足衞生需求。該公司的候選疫苗包括冠狀病毒候選疫苗NVX-CoV2373，它正在進行兩項第三階段試驗、一項IIb階段試驗和一項I/II階段試驗；NanoFlu，一種處於第三階段臨牀試驗的季節性四價流感疫苗候選產品；以及ResVax，一種呼吸道合胞病毒(RSV)融合(F)蛋白質納米顆粒疫苗候選產品。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
- 免費獲取StockNews.com關於Novavax的研究報告(NVAX)
- 3M、霍尼韋爾、通用電氣在季度報告後收購嗎？
- 這隻國防股票的基本面和技術面都看漲
- CVS和Walgreens展示為什麼投資目標很重要
- 索菲金融股票終於準備好為投資者買單了嗎？
- 美敦力和直覺外科公司準備實現大增長嗎？
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
接受Novavax Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Novavax和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。